Ichnos Cyril Konto, President & CEO of Ichnos Sciences comments on the company’s unique approach to finding new cancer treatments, the possibility of becoming fully independent from parent company Glenmark Pharmaceuticals and the licensing agreement Ichos has with Almirall for the IL-1RAP antagonist, ISB 880. … the Ichnos team has further…
USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…
Mexico COVID-19 has highlighted the importance of secure regional pharma supply chains across the globe, not least in Mexico where the state of Hidalgo has signed a deal with six Indian generics firms to establish a pharma hub for manufacturing and logistics. One of the leading pharma markets in Latin…
USA Two leading executives in the US generics market outline why robust company culture is key to attracting top talent that might otherwise gravitate towards the traditional research-driven industry. Talent attraction in the US generics market could potentially become a serious problem in the next few years. Ed Price, president…
USA So far in 2020 PharmaBoardroom has conducted interviews with several key stakeholders in US healthcare. We have heard from leaders the US FDA, as well as representatives of patient groups, health insurance providers, and firms operating in the US on what they consider the most pressing issues facing US healthcare.…
USA Robert Matsuk, president of Glenmark North America, introduces the scope of the company’s operations in the US – including a manufacturing facility that obtained its first approval in 2019. Matsuk describes the unique business model a generic player in the US needs to maintain its competitiveness and conveys the role…
Switzerland The Chief Scientific Officer and President of Glenmark Pharmaceuticals Swiss R&D Center elaborates on Glenmark’s endeavor to venture up the pharmaceutical value chain and discusses the company’s R&D strategy. Furthermore, he highlights the significance of strategic partnerships in today’s pharmaceutical R&D efforts. You have spent 23 years working in large…
Philippines Maria Bella Aranas, Country Manager of Glenmark Philippines, discusses the affiliates growing product portfolio in the country and their plans to further expand into different therapeutic areas. She also discusses the impressive performance of the affiliate, which currently is the largest in terms of volume and sales in the Philippines.…
development Glenmark’s country manager for Argentina discusses Argentina’s development expertise and how companies like Glenmark can capitalize on it through partnerships and collaborations. How did you become part of Glenmark, and what was your main objective when you took the helm in Argentina? I joined Glenmark five years ago as…
Glenmark Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it across 140 countries. What stage of the process are you in? When will we see India’s first novel drug in…
See our Cookie Privacy Policy Here